Q99.2 Insurance Policy Changes

ICD-10 Q99.2 is officially defined as "Fragile X chromosome." code Q99.2 is referenced in 6 tracked payer policy changes from Wisconsin Medicaid (ForwardHealth), Aetna, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Q99.2 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Wisconsin Medicaid (ForwardHealth) · Effective Oct 1, 2026Medium impact
ForwardHealth Covers Dental Case Management for Members With Special Health Care Needs
Beginning October 1, 2026, ForwardHealth covers dental case management for members with special health care needs, reimbursed under CDT code D9997 at $100 per visit. Prior authorization is required for more than one visit per member within 180 days, for D9997 billed with moderate to deep dental sedation in that period, for a member whose diagnosis is not a qualifying code but has documented medical necessity, and when the place of service is 15 (Mobile Unit). Prior authorization is not required for the first visit per member, per provider, every six months (180 days).
Aetna · Identified Oct 4, 2026Medium impact
Genetic Testing (CPB 0140, reviewed 2026-08-18)
Aetna covers genetic testing only when the criteria for the specific condition are met, and it considers testing outside those criteria experimental, investigational, or unproven, including testing for Parkinson disease, essential tremor, coronary artery disease (except testing for familial hypercholesterolemia), and type 2 diabetes other than MODY. Multi-gene panels for inherited cancers are covered only for members with a personal or family history of a related cancer when more than one inherited cancer syndrome could explain the presentation and the panel is more efficient than separate tests, and genetic testing for inherited cancers is a once-in-a-lifetime benefit. Expanded carrier screening for people who are pregnant or planning a pregnancy is covered when the panel includes cystic fibrosis, spinal muscular atrophy, and/or hemoglobinopathies, unless previously performed, and the results will be used in managing the pregnancy or for family planning; whole exome or whole genome sequencing is covered for an unexplained congenital or neurodevelopmental disorder when its listed criteria are met, and whole genome sequencing after a non-diagnostic whole exome test is considered not medically necessary.
Aetna · Identified Aug 19, 2026Medium impact
Invasive Prenatal Diagnosis of Genetic Diseases (CPB 0358, reviewed 2026-05-22)
Aetna's Clinical Policy Bulletin 0358 considers invasive prenatal diagnosis by chorionic villus sampling (CVS), genetic amniocentesis, and percutaneous umbilical blood sampling (PUBS, cordocentesis) medically necessary for diagnosing fetal chromosomal abnormalities. Preimplantation genetic testing for monogenic disorders (PGT-M) is medically necessary only when the listed criteria are met, including a known carrier parent for the specific indication, a specific identified mutation, and a procedure that eliminates the need for later invasive prenatal diagnosis. PGT-A, PGT-M for fetal chromosomal abnormalities, PGT-M to determine HLA status for stem cell donation, multigene panels at PGT-M testing, and invasive screening or PGT for a variant of uncertain significance are considered experimental, investigational, or unproven, as are the Igenomix PGT-M, PGT-SR, Smart PGT-A and Smart PGT-A Plus tests, the IriSight Prenatal Analysis, and the Natera Spectrum PGT-M test.
Aetna · Identified Aug 18, 2026Medium impact
Thalamotomy (CPB 0153, reviewed 2026-03-30)
Aetna considers unilateral thalamotomy medically necessary for abolishing tremor and rigidity in members with dystonia, Parkinson's disease, spasmodic torticollis, or tremor who meet all listed selection criteria, including a positive initial response to medication that later became refractory, screening by a neurologist with movement disorders expertise, and severe, incapacitating tremor where medical therapy has failed. Focused ultrasound thalamotomy is covered for severe essential tremor inadequately responsive to medical therapy, gamma knife thalamotomy is covered for severe essential tremor or for refractory disabling tremor and rigidity from Parkinson's disease, and thalamotomy is covered as a last resort for malignant pain when all listed criteria are met. Bilateral thalamotomy, focused ultrasound thalamotomy for tremor syndromes other than essential tremor, and thalamotomy for non-malignant pain are considered experimental, investigational, or unproven.
Aetna · Identified Aug 14, 2026Medium impact
Sensory and Auditory Integration Therapy (CPB 0256, reviewed 2026-04-15)
Aetna considers sensory integration therapy and auditory integration therapy (also known as auditory integration training) experimental, investigational, or unproven for the management of persons with various communication, behavioral, emotional, and learning disorders and for all other indications. The effectiveness of these therapies is unproven. CPT code 97533 is not covered for the indications listed in this policy, and the listed ICD-10 codes are not covered for those indications either.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Genetic Testing for FMR1 Variants (including Fragile X Syndrome)
Genetic testing for FMR1 variants may be considered medically necessary for individuals with characteristics of fragile X syndrome or a fragile X-associated disorder, and for individuals with a personal or family history of fragile X syndrome who are seeking reproductive counseling. Genetic testing for FMR1 variants is investigational for all other uses. Cytogenetic testing is no longer considered an acceptable diagnostic method according to American College of Medical Genetics and Genomics standards.

Watch Q99.2

Get one email when a payer policy names Q99.2, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code Q99.2?

There are 6 tracked policy changes affecting code Q99.2, including updates from Wisconsin Medicaid (ForwardHealth), Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code Q99.2?

Payers that have issued tracked updates for code Q99.2 include: Wisconsin Medicaid (ForwardHealth), Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code Q99.2 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code Q99.2. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code Q99.2?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

ForwardHealth Covers Dental Case Management for Members With Special Health Care Needs

Genetic Testing (CPB 0140, reviewed 2026-08-18)

Invasive Prenatal Diagnosis of Genetic Diseases (CPB 0358, reviewed 2026-05-22)

Thalamotomy (CPB 0153, reviewed 2026-03-30)

Sensory and Auditory Integration Therapy (CPB 0256, reviewed 2026-04-15)

Genetic Testing for FMR1 Variants (including Fragile X Syndrome)

What insurance policy changes affect code Q99.2?

Which payers have updated policy for code Q99.2?

How do I get notified when code Q99.2 policy changes?

Why do payers change policies for code Q99.2?